Published in J Clin Oncol on January 05, 2009
Hodgkin lymphoma. J Clin Invest (2012) 1.41
Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood (2012) 1.23
Current role of FDG PET/CT in lymphoma. Eur J Nucl Med Mol Imaging (2014) 1.06
Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy. Haematologica (2012) 1.00
State of the art in the treatment of Hodgkin lymphoma. Nat Rev Clin Oncol (2012) 0.95
Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. Br J Haematol (2015) 0.84
Hodgkin lymphoma, version 2.2015. J Natl Compr Canc Netw (2015) 0.82
Advanced hodgkin lymphoma: a new era of therapy. Mediterr J Hematol Infect Dis (2014) 0.81
Pitfalls in diagnostic hematopathology -- Part II. Int J Clin Exp Pathol (2009) 0.80
Chemotherapy: Hodgkin lymphoma--absence of evidence not evidence of absence! Nat Rev Clin Oncol (2011) 0.80
Advances in the treatment of relapsed or refractory Hodgkin's lymphoma. Oncologist (2012) 0.80
Chemotherapy: Advanced Hodgkin lymphoma--balancing toxicity and cure. Nat Rev Clin Oncol (2011) 0.79
Hodgkin's lymphoma therapy: past, present, and future. Expert Opin Pharmacother (2010) 0.78
Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats. Adv Hematol (2010) 0.78
Osteonecrosis detected by whole body magnetic resonance in patients with Hodgkin Lymphoma treated by BEACOPP. Eur Radiol (2016) 0.78
A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian cancer. Cancer Chemother Pharmacol (2011) 0.76
Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography. Adv Hematol (2010) 0.76
The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future. Adv Hematol (2011) 0.76
Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study. Haematologica (2015) 0.75
Intensified ChlVPP/ABVVP chemotherapy regimen and pegfilgrastim support in advanced Hodgkin lymphoma. Ecancermedicalscience (2010) 0.75
Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma. Adv Hematol (2011) 0.75
First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphoma. Bone Marrow Transplant (2016) 0.75
A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity. Br J Cancer (2013) 0.75
Clinical features and treatment outcomes of Hodgkin's lymphoma in Hong Kong Chinese. Arch Med Sci (2014) 0.75
Pediatric Hodgkin Lymphoma: on the road to a 'radiotherapy-free' cure rate?-Commentary on a report on final results of the Multinational Trial GPOH-HD95. Transl Pediatr (2013) 0.75
Hodgkin disease-an ever-evolving therapy. Rambam Maimonides Med J (2014) 0.75
Tailored strategies for radiation therapy in classical Hodgkin's lymphoma. Crit Rev Oncol Hematol (2012) 0.75
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: A systematic review and meta-analysis of randomized clinical trials. Haematologica (2017) 0.75
BRAF mutations in hairy-cell leukemia. N Engl J Med (2011) 7.05
Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med (2012) 5.87
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet (2009) 4.25
Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol (2007) 3.99
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol (2013) 3.58
Pure red-cell aplasia and epoetin therapy. N Engl J Med (2004) 3.49
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood (2010) 2.84
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood (2008) 2.68
Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood (2002) 2.57
Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood (2003) 2.56
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood (2011) 2.37
Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica (2002) 2.34
Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med (2014) 2.33
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica (2008) 2.29
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis. Br J Haematol (2013) 2.28
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol (2010) 2.27
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res (2009) 2.25
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol (2010) 2.25
Reassessments of ESAs for cancer treatment in the US and Europe. Oncology (Williston Park) (2010) 2.22
Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol (2009) 2.19
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. J Clin Oncol (2007) 2.14
Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol (2006) 2.09
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica (2012) 1.98
Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. BMC Cancer (2007) 1.96
CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J Clin Oncol (2014) 1.92
First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol (2011) 1.84
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest (2008) 1.81
High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. Leuk Lymphoma (2012) 1.77
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol (2010) 1.76
Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study. Haematologica (2004) 1.72
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood (2011) 1.69
Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program. Cancer (2011) 1.67
Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood (2009) 1.65
Incidence of second neoplasia in patients with B-cell chronic lymphocytic leukemia treated with chlorambucil maintenance chemotherapy. Leuk Lymphoma (2006) 1.64
Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood (2003) 1.62
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi. J Clin Oncol (2011) 1.61
Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. Leuk Lymphoma (2011) 1.60
High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol (2003) 1.58
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther (2010) 1.58
MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years. Neurology (2014) 1.58
A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias. Am J Hematol (2008) 1.57
Prolonged left ventricular twist in cardiomyopathies: a potential link between systolic and diastolic dysfunction. Eur J Echocardiogr (2011) 1.57
Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol (2012) 1.56
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leuk Lymphoma (2007) 1.54
Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol (2012) 1.53